Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Tumor heterogeneity presents a significant challenge for developing effective targeted therapies.
• KRAS mutations are common drivers in lung adenocarcinoma, necessitating specific therapeutic strategies.

Purpose of the Study:

• To deconvolute tumor heterogeneity in KRAS-mutant lung adenocarcinomas using single-cell RNA sequencing.
• To identify and characterize a conserved tumor-specific subpopulation associated with mutant KRAS.
• To evaluate the therapeutic potential of targeting BMI-1 activity with PTC596 in a murine model of KRAS-mutant lung cancer.

Main Methods:

• Single-cell RNA sequencing was employed to analyze tumor heterogeneity in human and murine lung adenocarcinoma models.
• Magnetic Resonance Imaging (MRI) was used to assess tumor volume changes post-treatment.
• In vivo treatment with PTC596, an inhibitor affecting BMI-1 activity, was administered to the murine model.

Main Results:

• A distinct tumor-specific subpopulation associated with mutant KRAS was identified and found to be conserved across human and murine lung cancers.
• In vivo treatment with PTC596 led to a significant decrease in tumor size as observed by MRI.
• Single-cell transcriptomics revealed a near-complete ablation of the mutant-KRAS-associated subpopulation following PTC596 treatment.

Conclusions:

• The study identified a pharmacologically targetable, tumor-associated subpopulation in KRAS-mutant lung adenocarcinomas.
• Targeting BMI-1 activity with PTC596 demonstrates efficacy in reducing tumor burden and eliminating this specific cancer cell population.
• These findings provide a strong foundation for developing novel targeted therapies for KRAS-mutant lung adenocarcinomas.